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a  b  s  t  r  a  c  t
The  identiﬁcation  of  subcutaneous  metastatic  lesions  from  primary  visceral  malignancies  has  increased
over  time,  probably  due  to an  increase  in  the  awareness  of  their  presentation  and  an  increase  in can-
cer  survival  times.  Although  the rate  of  subcutaneous  metastases  from  breast,lung  and  colon  cancer  is
more  signiﬁcant,  the  incidence  of subcutaneous  metastases  from  esophageal  carcinomas  is  very low.vailable online 29 October 2016
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These  metastatic  lesions  usually  present  metachronously  and  may signify  advanced  disease  and  poor
prognosis.  We report  three  cases  with  early  stage  esophageal  adenocarcinoma  treated  with  surgery  with
curative  intent  presenting  with  subcutaneous  metastases  two  months,  two  years  and  three  years  after
their esophagectomy.
©  2016  The  Authors.  Published  by Elsevier  Ltd  on  behalf  of IJS  Publishing  Group  Ltd.  This  is an  open
he CCase report access  article  under  t
. Introduction
Cutaneous metastases from visceral malignancies have been
eported in 5–10% of cases [1–3]. Breast, lung and colon cancers
re the tumors most likely to spread to the dermis and commonly
resent after the 6th decade of life [2]. In a large cohort of 838
atients with esophageal cancer, a rate of distant metastasis of
pproximately 20% was reported [4]. However, these metastatic
esions were most commonly seen in abdominal lymph nodes
45%), liver (35%) and lung (20%), with a signiﬁcantly lower rate
f 1% for metastatic lesions involving the skin [4].
Subcutaneous metastatic lesions have been reported to arise
rom both esophageal adenocarcinomas and squamous cell can-
ers. However, their presentation is very rare and their incidence
ay  depend on the prevalence of the primary carcinoma, with
sophageal adenocarcinoma being more common in white males,
nd squamous cell cancer more common in white women, blacks,
nd Asians [5].
The location of subcutaneous metastasis from esophageal car-
inoma is variable. The scalp, neck and face have been reported as
ommon locations [2,6,7], although metastatic lesions to the chest
all, back and axillary regions have been reported as well [6,8–10].
hese lesions are indeed rare.
Associated factors predicting the risk for subcutaneous metas-
asis are not yet well known. However, poorly differentiated
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adenocarcinomas and the evidence of signet ring cell features may
increase the risk of cutaneous spreading [11]. The identiﬁcation
of these pathological patterns after surgical resection may  help
in establishing the metastatic risk and may  aid in the follow-up
planning for this group of patients.
The overall prognosis and survival rates for esophageal ade-
nocarcinoma is poor at 15% [5,12], although early stage tumors
(T2N0M0 stage or less) have adequate cure rates of around 50% after
surgical resection [13,14]. Patients with subcutaneous metastatic
disease have a signiﬁcantly poorer prognosis with reported sur-
vival rates of less than one year after the identiﬁcation of metastatic
lesions, and treatment is usually aimed to palliation through pos-
sible resection with chemotherapy and radiotherapy [7,15–17].
We describe three cases with early stage esophageal adeno-
carcinoma presenting with subcutaneous metastases between two
months and three years after esophagectomy with curative intent.
2. Presentation of cases
2.1. Patient 1
A 61 year old man  with a history of reﬂux esophagitis was
evaluated for progressive dysphagia and 10% weight loss in three
months. Endoscopy revealed long segment Barrett’s esophagus and
a fungating mass at the GE junction (Siewert II) nearly obstructing
the lumen. Biopsies showed poorly differentiated adenocarci-
noma with signet ring cell features (Fig. 1A). PET-CT showed a
4.6 cm hypermetabolic mass with standard uptake value (SUV) of
11.8 without evidence of lymph node or distant metastasis. He
roup Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Fig 1. Biopsy showed an inﬁltrating poorly differentiated adenocarcinoma with signet ring cell features (arrow) (A). After chemoradiation therapy, the surgical resection
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ymph  nodes involvement. Chest wall metastasis (C) and excisional biopsy demon
arrow) (D) morphologically consistent with the esophageal tumor.
eceived neoadjuvant chemoradiation therapy with carboplatinum
nd taxotere and 50 Gy of external beam radiation in 25 fractions.
ost-treatment PET-CT showed a 58% decrease in the SUV value and
o evidence of distant disease. An open McKeown esophagectomy
as performed. The ﬁnal pathologic stage was  T2N0M0 with no
nvolvement of the 19 lymph nodes examined and no evidence of
ymphovascular invasion (Fig. 1B). Two months later he presented
ith shortness of breath and a palpable 7 cm mass cephalad to a
eft chest tube scar (Fig. 1C). CT scan revealed the chest wall mass,
 moderate sized left pleural effusion with no tumor cells on cytol-
gy, and pulmonary and hepatic metastases. The chest wall lesion
as metastatic poorly differentiated adenocarcinoma morpholog-
cally similar to the patient’s known esophageal cancer, also with
ignet cell features (Fig. 1D). The patient died one month later.
.2. Patient 2
A 69-year-old man  with a long history of Barrett’s esophagus
as diagnosed with a distal esophageal (Siewert I) moderately
o poorly differentiated adenocarcinoma. Endoscopic ultrasound
howed a non-circumferential, non-obstructing mass with two
alignant-appearing lymph nodes, which was staged as T2N1MX
y endosonographic criteria. PET-CT showed a mild hyperme-
abolic area in the distal esophagus with SUV of 3.8 and no evidence
f hypermetabolic lymph nodes or distant metastasis. This patient
id not undergo neoadjuvant therapy prior to surgical resection
ith a minimally invasive Ivor Lewis esophagectomy. The ﬁnaltiated adenocarcinoma invading into the muscularis propria (B) with no regional
d a metastatic poorly differentiated adenocarcinoma with signet ring cell features
pathologic stage was  T1bN0M0 with 23 lymph nodes negative
for metastasis and an absence of lympho-vascular involvement
(Fig. 2A). Two years later he presented with a tender subcutaneous
mass measuring 2 × 2 x 1 cm on his right temple. Biopsy evidenced
metastatic moderate to poorly differentiated adenocarcinoma with
similar morphology to the original tumor and positive stains for
carcinoembryonic antigen (CEA) and mucin, as well as cytokeratin
7 (CK7), conﬁrming an upper gastrointestinal source (Fig. 2B–D).
PET-CT showed diffuse metastatic disease in the bones and lungs.
He received palliative chemotherapy and died two  months later.
2.3. Patient 3
A 61-year-old man  presented with progressive dysphagia and
weight loss of 25 pounds in three months. Endoscopy revealed a
non-circumferential mass 35 cm from the incisors. Biopsy demon-
strated poorly differentiated adenocarcinoma with focal signet ring
cell features (Fig. 3A). Endoscopic ultrasound was done showing
a partially obstructing mass with clinical stage T3N0MX. PET-CT
showed hypermetabolic activity at the gastroesophageal junction
(Siewert II) with SUV of 9.6 and no evidence of metastatic dis-
ease. Induction chemoradiotherapy was done followed by an open
McKeown esophagectomy. He had a complete pathologic response
with 14 negative lymph nodes and no lymphovascular invasion in
the pathology report. Approximately three years later the patient
presented with a small nodule on his scalp, which was  excised
and identiﬁed as a poorly differentiated metastatic adenocarci-
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Fig. 2. Esophagectomy specimen showed a moderately differentiated adenocarcinoma (A). Punch biopsy of a subcutaneous metastasis found in the right temple revealed
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ucicarmine (D), but negative for cytokeratin 20, thyroid transcription factor 1 a
sophageal adenocarcinoma.
oma with mucin containing cells. It stained positive for Villin and
K7, indicating an upper GI source (Fig. 3B–D). The patient started
hemotherapy at another institution and was lost to follow-up.
. Discussion
The incidence of subcutaneous metastases from underlying
umors has increased over time [2]. However, the development
f cutaneous metastases from esophageal cancer is still very rare.
e present three patients who had early stage disease pathologi-
ally conﬁrmed after surgery, who nonetheless showed cutaneous
etastases at variable time points after esophagectomy.
Although these patients had no lymphovascular invasion within
he primary tumor, no pathological evidence of disease in any of the
ymph nodes resected, and received treatment with curative intent
ith good pathologic response, cutaneous metastases were evident
etween as short as two months and as long as three years after
reatment. All three patients had adenocarcinoma, two  of them
ad primary tumors with signet ring cell features, indicating more
ggressive behavior [11], and all three cases demonstrated moder-
te to poorly differentiated primary tumors, which also indicates a
ore aggressive disease.
Two of our cases showed metastases to the scalp and face, ineeping with the trend mentioned previously [2,6]. One case how-
ver, presented with metastases to the chest wall separate from
n incision. This demonstrates that subcutaneous metastases may
evelop within a variable interval of time, to variable locations,showed tumor cells positive for cytokeratin 7 (C), carcinoembryonic antigen and
ster of differentiation 31, consistent with a metastasis from the patient’s known
and can occur in patients with early stage disease and no evidence
of lymphovascular spread at the time of resection. These unusual
recurrences complicate the search for ideal biomarkers that would
help stratify outcomes for esophageal adenocarcinoma.
It has been found that any form of treatment can signiﬁcantly
improve survival time in patients with oligometastases in the form
of fewer than three metastases, although this may be biased by
patient selection [18].
4. Conclusion
Although cutaneous metastases from esophageal adenocarci-
noma are rare and unusual, they cannot be dismissed, even in
patients with low-grade tumors that have been resected with cura-
tive intent and shown complete pathological response. Prompt
identiﬁcation and diagnosis is especially crucial given the poor
prognosis of patients who  are found to have subcutaneous metas-
tases. Once these metastases are identiﬁed, treatment to improve
survival time can be offered and palliative measures can be started.
Patients should be followed to monitor for any metastases, includ-
ing cutaneous metastases with special consideration for the scalp
and face. Additionally, any cutaneous lesions found either by the
patient or on follow-up should be investigated immediately for
possible metastatic features, regardless of length of interval since
primary tumor resection. It is also important to study any biomark-
ers involved in such lesions so that we may  one day be better able to
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This case report has been written in line with the SCARE criteria
19].
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